ONGAR, England--(BUSINESS WIRE)--Selcia Ltd today announced the successful completion of a drug discovery project with ExonHit Therapeutics SA (Paris, France), using Selcia’s fragment screening technology. Novel and weak affinity hits were identified from Selcia’s Fragment Library, using their proprietary CEfrag™ technique. ExonHit Therapeutics are now advancing the viable hits for optimisation.
